Esperion Therapeutics Inc. (ESPR) Shares Down 4.4%
Esperion Therapeutics Inc. (NASDAQ:ESPR) shares fell 4.4% during trading on Wednesday . The company traded as low as $12.67 and last traded at $12.92, with a volume of 375,347 shares traded. The stock had previously closed at $13.51.
A number of brokerages have commented on ESPR. JMP Securities restated a “buy” rating and set a $67.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, June 16th. Royal Bank Of Canada cut Esperion Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the stock from $30.00 to $15.00 in a research note on Wednesday, June 29th. JPMorgan Chase & Co. cut Esperion Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $50.00 to $15.00 in a research note on Wednesday, June 29th. Barclays PLC cut Esperion Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $28.00 to $13.00 in a research note on Wednesday, June 29th. Finally, Citigroup Inc. restated a “buy” rating and set a $22.00 price objective (down previously from $36.00) on shares of Esperion Therapeutics in a research note on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. Esperion Therapeutics has an average rating of “Hold” and an average target price of $24.40.
The company’s market capitalization is $297.89 million. The company’s 50-day moving average is $11.06 and its 200-day moving average is $14.22.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/esperion-therapeutics-inc-espr-shares-down-4-4.html
Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.16. During the same quarter in the prior year, the firm earned ($0.55) earnings per share. On average, equities research analysts predict that Esperion Therapeutics Inc. will post ($3.37) EPS for the current fiscal year.
In other Esperion Therapeutics news, Director Mark E. Mcgovern acquired 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 6th. The stock was purchased at an average cost of $10.00 per share, for a total transaction of $50,000.00. Following the completion of the acquisition, the director now owns 600 shares of the company’s stock, valued at approximately $6,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 35.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Quantitative Investment Management LLC purchased a new stake in Esperion Therapeutics during the second quarter worth about $111,000. Advisor Group Inc. purchased a new stake in Esperion Therapeutics during the second quarter worth about $140,000. Stifel Financial Corp boosted its stake in Esperion Therapeutics by 10.6% in the second quarter. Stifel Financial Corp now owns 15,017 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 1,438 shares during the period. Rhumbline Advisers boosted its stake in Esperion Therapeutics by 27.0% in the second quarter. Rhumbline Advisers now owns 17,186 shares of the biopharmaceutical company’s stock worth $170,000 after buying an additional 3,657 shares during the period. Finally, ProShare Advisors LLC boosted its stake in Esperion Therapeutics by 1.3% in the second quarter. ProShare Advisors LLC now owns 18,533 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 238 shares during the period. Institutional investors own 65.22% of the company’s stock.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company’s segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.